Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5244761 | 0.90 | HSD11B1 (0.65) | HSD11B1 | |
| SCHEMBL5289924 | 0.78 | TNNI3 (0.58) | HSD11B1 | |
| SCHEMBL3213850 | 0.77 | HSD11B1 (0.78) | HSD11B1 | |
| SCHEMBL3215217 | 0.77 | HSD11B1 (0.72) | HSD11B1 | |
| SCHEMBL3210183 | 0.76 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL5244389 | 0.76 | MEN1 (0.56) | — | |
| SCHEMBL5439348 | 0.74 | HSD11B1 (0.72) | HSD11B1 | |
| SCHEMBL8160562 | 0.74 | HSD11B1 (0.57) | HSD11B1 | |
| SCHEMBL3604873 | 0.73 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL3198957 | 0.73 | HSD11B1 (0.65) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758873-A1 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | claimed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282818-A1 | Ubiquitin ligase inhibitors | NEDD4, TRAF6, XIAP | HSD11B1 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.